期刊文献+
共找到133篇文章
< 1 2 7 >
每页显示 20 50 100
Short-term effects of intravitreal triamcinolone acetonide injection on ocular blood flow evaluated with color Doppler ultrasonography 被引量:4
1
作者 Mustafa Alpaslan Anayol Yasin Toklu +5 位作者 Elif Asik Kamberoglu Sabri Raza Hasan Basri Arifoglu Huseyin Simavli Ayse Gul Kocak Altintas Saban Simsek 《International Journal of Ophthalmology(English edition)》 SCIE CAS 2014年第5期811-815,共5页
AIM:To evaluate the changes in ocular blood flow with color Doppler ultrasonography(CDU) after intravitreal triamcinolone acetonide(IVTA) injection.METHODS:A total of 46 patients who underwent IVTA(4 mg/0.1 mL) inject... AIM:To evaluate the changes in ocular blood flow with color Doppler ultrasonography(CDU) after intravitreal triamcinolone acetonide(IVTA) injection.METHODS:A total of 46 patients who underwent IVTA(4 mg/0.1 mL) injection for diabetic macular edema(DME)(n =22), central retinal vein occlusion(CRVO)(n =12) and choroidal neovascular membrane(CNVM)(n =12) were included in the study. Peak systolic velocity(PSV), end diastolic velocity(EDV) and resistivity index(RI) were measured from the ophthalmic artery(OA), the central retinal artery(CRA) and the posterior ciliary artery(PCA)of each patient with CDU before, at the end of the first week and at the end of the first month following IVTA injection.RESULTS:In the DME group, PSV of OA at the first of the first month(mean ±SD)(37.48 ±10.87 cm/s) increased compared to pre-injection value(31.39 ±10.84 cm/s)(P =0.048). There was a statistically significant decrease(P =0.049) in PSV of CRA at the end of the first month(7.97±2.67 cm/s) compared to the pre-injection(9.47±3.37 cm/s).There was not any statistically significant difference onthe other parameters in the DME group. Also, there was not any statistically significant difference on the ocular blood flow values in the CRVO and CNVM groups.CONCLUSION:We observed that 4 mg/0.1 mL IVTA increased PSV of OA and decreased PSV of CRA in DME patients and did not have any effect on ocular blood flow values of CRVO and CNVM patients. 展开更多
关键词 intravitreal triamcinolone acetonide ocular blood flow diabetic macular edema central retinal vein occlusion choroidal neovascular membrane
下载PDF
Iatrogenic crystalline lens injury during intravitreal injection of triamcinolone acetonide: A report of two cases 被引量:1
2
作者 Jing Su Li-Jun Zheng Xin-Quan Liu 《World Journal of Clinical Cases》 SCIE 2019年第22期3784-3791,共8页
BACKGROUND Intravitreal injection has become an efficient approach for delivering drugs at therapeutic levels to the posterior segment in retinal diseases.However,the increased frequency and number of intravitreal inj... BACKGROUND Intravitreal injection has become an efficient approach for delivering drugs at therapeutic levels to the posterior segment in retinal diseases.However,the increased frequency and number of intravitreal injections have raised concerns about their side effects.As manipulation during surgery is relatively simple,details of the procedure are easily overlooked.Iatrogenic crystalline lens injury is a rare complication caused by improper manipulation during surgical procedures.We report two cases of crystalline lens injury during intravitreal injection of triamcinolone acetonide(TA)with the hope of providing an insight into this treatment.CASE SUMMARY Case 1 was a 62-year-old woman with macular edema caused by central retinal vein occlusion in her right eye,and Case 2 was a 65-year-old man with macular edema caused by branch retinal vein occlusion in his right eye.In view of the patients’condition and economic constraints,an intravitreal injection of TA was administered.Due to inappropriate manipulation during surgery,the lens was injured.The site of lens injury and clinical manifestations were different in the two cases.Symptomatic treatment and continuous follow-up were carried out.The therapeutic effect following phacoemulsification of the cataract was satisfactory.CONCLUSION Well-defined surgical incision under proper anesthesia,sufficient patient information and proficient anatomical skills of the physician are mandatory to prevent this rare adverse event.Careful and meticulous phacoemulsification of the cataract is suggested. 展开更多
关键词 CRYSTALLINE lens intravitreal injection triamcinolone acetonide Iatrogenicinjury Case REPORT
下载PDF
Different Dosages of Intravitreal Triamcinolone Acetonide Injections for Macular Edema Secondary to Central Retinal Vein Occlusion 被引量:6
3
作者 Yong Wei Huaizhou Wang +3 位作者 Fenghua Chen Zhongqiao Zu Chuncao Bi Xinguang Yang 《Eye Science》 CAS 2012年第3期152-157,共6页
Purpose:.To study the effect of intravitreal injections of triamcinolone acetonide (TA) for the treatment of macular edema secondary to central retinal vein occlusion.(CRVO).in a sample of Chinese patients from Shaanx... Purpose:.To study the effect of intravitreal injections of triamcinolone acetonide (TA) for the treatment of macular edema secondary to central retinal vein occlusion.(CRVO).in a sample of Chinese patients from Shaanxi province. Methods:.The 50 eyes from 50 patients were separated into three TA treatment groups:.17 patients were given 4 mg/0.1 ml,.19 patients were given 8 mg/0.2 ml,.and 14 patients were given 16 mg/0.4 ml. Patients were followed up for 12 months. Foveal thickness, intraocular pressure (IOP), and best-corrected visual acuity (BCVA) were measured. Results:.Macular edema responded well both anatomically and functionally to the TA injections. After the initial intravitreal injection,.macular edema recurred at 2-4 months in the low-dose group.(4 mg),.at 3-5 months in the medium-dose group (8 mg), and at 6-9 months in the high-dose group (16 mg)..No significant difference in BCVA or in foveal thickness were observed between the first intravitreal injection and the re-injection. There was no increase in IOP after re-injection of 16 mg TA,.if the patient did not have an elevated IOP after the initial intravitreal injection of 4/8 mg TA. Conclusion: A low dosage of TA (4 mg) administered via intravitreal injection might be useful as an initial treatment for macular edema secondary to CRVO..A higher dosage of TA (16mg) can be used if there is no IOP elevation with the initial TA injection. 展开更多
关键词 注射治疗 低剂量 视网膜 黄斑 水肿 继发 玻璃 阻塞
下载PDF
Intravitreal triamcinolone acetonide: a "real world" analysis of visual acuity, pressure and outcomes 被引量:1
4
作者 Victor Manuel Villegas Aaron Samuel Gold +2 位作者 Andrea Wildner Azeema Latiff Timothy Garrett Murray 《International Journal of Ophthalmology(English edition)》 SCIE CAS 2016年第5期789-791,共3页
Dear Sir,Triamcinolone acetonide(TA)is worldwide available therapeutic agent that is commonly used throughout medicine.TA remains a safe and important ophthalmic therapeutic agent even after the advent of angiogenes... Dear Sir,Triamcinolone acetonide(TA)is worldwide available therapeutic agent that is commonly used throughout medicine.TA remains a safe and important ophthalmic therapeutic agent even after the advent of angiogenesis inhibitors[1-2]. 展开更多
关键词 IOP TA analysis of visual acuity pressure and outcomes real world intravitreal triamcinolone acetonide
下载PDF
Safety of intravitreal triamcinolone acetonide:an electrophysiologic and histopathological study in rabbits
5
作者 Laila Hassan M.El-Shazly Amal Ahmad El-Gohary Ghada Ghanem El-Hossary 《International Journal of Ophthalmology(English edition)》 SCIE CAS 2013年第6期790-795,共6页
AIM:To evaluate the retinal safety of various doses of intravitreal triamcinolone acetonide(TA)in rabbits.METHODS:Thirty New Zealand albino rabbits were divided into five groups(six animals each).In group 1(control gr... AIM:To evaluate the retinal safety of various doses of intravitreal triamcinolone acetonide(TA)in rabbits.METHODS:Thirty New Zealand albino rabbits were divided into five groups(six animals each).In group 1(control group),each animal received a single intravitreal injection of 0.1 mL phosphate buffered saline.In groups2,3,4 and 5,each rabbit received a single intravitreal injection of 4,8,16 and 32mg of TA,respectively.Each dose was contained in 0.1 mL phosphate buffered saline.Clinical ocular examinations were performed before the injection and on the 1st,3rd,10th and 17th postinjection days.A standard dark adapted electroretinogram(ERG)was obtained before injection and on the 3rd,10th and 17th post-injection days.After17d,animals were sacrificed and their eyes prepared for pathological examination.RESULTS:By monitoring ERG as a functional index for the retina,intravitreal injection of 4mg TA showed no significant ERG changes.At doses of 8,16 and 32,hyper-abnormal responses in a-and b-waves of ERG were detected on the 3rd post-injection day.These changes gradually returned back to normal limits after17d.Histopathological examination of the retina of all animals showed no pathological changes.CONCLUSION:High doses of intravitreal TA seemed to have enhancing effects on the retinal function with gradual return to normal limits with no pathological changes detected in examined eyes. 展开更多
关键词 triamcinolone acetonide intravitreal injection ELECTRORETINOGRAM
下载PDF
Complications Following Inappropriate Intravitreal Triamcinolone Acetonide Injection
6
作者 Yukishige Nakaseko Mai Kamatani +2 位作者 Mineo Kondo Yukitaka Uji Masahiko Sugimoto 《Open Journal of Ophthalmology》 2012年第4期114-115,共2页
Purpose: Intravitreal Triamcinolone Acetonide (IVTA) is a useful treatment option for various intraocular diseases such as Macular Edema (ME). The treatment can cause several complications, including transient elevati... Purpose: Intravitreal Triamcinolone Acetonide (IVTA) is a useful treatment option for various intraocular diseases such as Macular Edema (ME). The treatment can cause several complications, including transient elevation of intraocular pressure and cataract formation. Here, we describe an atypical complication of IVTA. Case: A 60-year-old Japanese man presented with ME associated with central retinal vein occlusion. We performed intravitreal injection of 4 mg of TA. However, the drug spread behind the posterior lens capsule and also flowed into the anterior chamber. Although the amount of TA particles behind the lens capsule decreased over time, these particles persisted for more than 2 months. Conclusion: Although IVTA is an easy and effective treatment for ME, TA is harmful when injected into inappropriate regions of the eye. Accurate IVTA injection is important for effective treatment. 展开更多
关键词 triamcinolone acetonide intravitreal INJECTION
下载PDF
Macular laser photocoagulation with or without intravitreal triamcinolone pretreatment for diabetic macular edema: a result from five randomized controlled trials 被引量:10
7
作者 Xiang-Dong Liu Xiao-Dong Zhou +1 位作者 Zhi Wang Yong-Ming Shen 《International Journal of Ophthalmology(English edition)》 SCIE CAS 2016年第1期132-138,共7页
AIM:To assess possible benefits of intravitreal triamcinolone acetonide(IVTA)injection as pretreatment for macular laser photocoagulation(MLP)in patients with diabetic macular edema(DME).·METHODS:Publishe... AIM:To assess possible benefits of intravitreal triamcinolone acetonide(IVTA)injection as pretreatment for macular laser photocoagulation(MLP)in patients with diabetic macular edema(DME).·METHODS:Published randomized controlled trials(RCTs)concerning MLP with or without IVTA pretreatment for DME were retrieved from databases CNKI,Medline,EMbase,Web of Science,and the Cochrane Library.A Meta-analysis on eligible studies was conducted using Rev Man 5.0 software.Two investigators independently assessed the quality of the trials and extracted data.Main outcome measures included the change in best-corrected visual acuity(BCVA),difference in central macular thickness(CMT)and adverse events reporting in particular elevated intraocular pressure within the follow-up period.The results were pooled using weight mean difference(WMD)or odds risk(OR)with their corresponding 95%confidence intervals(CI).A fixed-or random-effect model was employed depending on the heterogeneity of the inclusion trials.·R ESULTS:Finally,five independent RCTs were identified and used for comparing MLP with IVTA pretreatment(131 eyes)with MLP alone(133 eyes,control group).The overall study quality was relatively higher according to the modified Jadad scale.The Metaanalysis showed that MLP with IVTA pretreatment significantly reduced CMT at one,three and six months(=0.002,0.0003 and 0.04,respectively),compared with MLP alone.The IVTA pretreatment group showed statistically significant improvements in BCVA at the one-month follow up as compared with the control group(=0.03).At three-and six-month follow up,there was a beneficial trend towards improving visual acuity in the IVTA pretreatment group without statistical significance between groups(=0.06 and 0.20,respectively).The incidence of elevation of intraocular pressure was significantly higher in the IVTA pretreatment group than in the control group(〈0.0001).No evidence of publication bias was present according to Begg’s test and Egger’s test.There was a low level of heterogeneity in the included studies.·CONCLUSION:This Meta-analysis indicates that MLP with IVTA pretreatment has a better therapeutic effect in terms of CMT reduction and earlier(1mo)visual improvement for patients with DME as compared with MLP alone.Further confirmation with rigorously welldesigned multi-center trials is needed. 展开更多
关键词 PHOTOCOAGULATION intravitreal injection triamcinolone acetonide diabetic macular edema
下载PDF
Filter Connected with Three-way Cock in Remove of the Vehicle in Triamcinolone Acetonide
8
作者 Lei Du Yiqiao Xing Changzheng Chen 《眼科学报》 2006年第3期156-159,165,共5页
Purpose: To evaluate the clinical effect of 5-μm pore filter connected with three-way cock by removing the vehicle in triamcinolone acetonide(TA) suspension. Methods: Through 5-μm pore filter connected with three-wa... Purpose: To evaluate the clinical effect of 5-μm pore filter connected with three-way cock by removing the vehicle in triamcinolone acetonide(TA) suspension. Methods: Through 5-μm pore filter connected with three-way cock, TA suspension was replaced by intraocular irrigating solution. The new suspension has been applied to 60 cases of diabetic branch retinal vein occlusion,diabetic macular edema and age-related macular degeneration patients through intravitreal injection. It was also been applied to 41 cases of diabetic retinopathy, epimacular membrane, proliferative vitreoretinopathy and idiopathic macular hole patients to assist pas plana vitrectomy (PPV). Whether TA particles can adhere to posterior hyaloid cortex, epiretinal membrane and internal limiting membrane during the surgery have been observed. During follow up, corrected visual acuity and intraocular pressure were recorded. Results: Five μm pore filter connected with three-way cock can remove the vehicle in TA suspension successfully and retain TA particles. When the new suspension was applied to assist PPV, it can adhere to posterior hyaloid cortex, epiretinal membrane, internal limiting membrane and visualized them clearly. In all the 41 cases that underwent PPV surgery, visual acuity of 30 cases increased or remained stable. Intraocular hypertension happened in 4 cases. Two cases of the 41 patients had cataract formation during follow up. In the 60 cases that underwent TA intravitreal injection, 45 cases increased their visual acuity at least 2 lines. Intraocular hypertension happened in 17 cases and 4 patients had cataract formation. None of the 101 patients caught endophthalmitis or other serious complications. Conclusion: Filter connected with three-way cock can remove the vehicle in TA suspension effectively and this procedure can be applied to intravitreal injection or PPV. This manipulation is so simple that it deserves to be popularized for clinical use. 展开更多
关键词 triamcinolone acetonide Safety VITRECTOMY intravitreal injection
下载PDF
Intravitreal bevacizumab with or without triamcinolone acetonide for diabetic macular edema: a meta-analysis of randomized controlled trials 被引量:7
9
作者 Liu Xiangdong Zhou Xiaodong Wang Zhi Li Tao Jiang Bo 《Chinese Medical Journal》 SCIE CAS CSCD 2014年第19期3471-3476,共6页
Background Intravitreal anti-vascular endothelial growth factor (anti-VEGF) drugs and corticosteroids are being widely used to treat diabetic macular edema (DME). The purpose of this study was to evaluate further ... Background Intravitreal anti-vascular endothelial growth factor (anti-VEGF) drugs and corticosteroids are being widely used to treat diabetic macular edema (DME). The purpose of this study was to evaluate further the efficacy and safety of intravitreal bevacizumab (IVB) alone in comparison with intravitreal bevacizumab combined with triamcinolone acetonide (IVB/IVT) in the treatment of DME. Methods Pertinent publications were identified through CNKI, PubMed, Medline, EMBASE, and the Cochrane Controlled Trials Register up to November 30, 2013. Two investigators independently assessed the quality of the trials, and changes in central macular thickness (CMT) and best-corrected visual acuity (BCVA) were extracted at 6 weeks and 3, 6, 12, and 24 months after the initial treatment. A meta-analysis was carried out to compare the results between the groups receiving IVB and IVB/IVT using the software RevMan 5.0. Results A total of six randomized controlled trials (RCTs) were identified and included. The meta-analysis revealed that a significant reduction of the CMT was observed at 3 months after the initial treatment in the IVB/IVT group compared to the IVB group (P=-0.001). Also, changes in CMT at 6 weeks and 6, 12, and 24 months did not vary significantly between the IVB and IVB/IVT groups (P=0.53, 0.76, 0.34, and 0.09, respectively). Similarly, changes in BCVA at 6 weeks and 3, 6, 12, and 24 months also did not vary significantly between the two groups (P=-0.66, 0.98, 0.81, 0.07, and 0.80, respectively). The results were robust to sensitivity analyses. However, the rate of intraocular pressure (IOP) rise after intravitreal injections varied significantly between the IVB and IVB/IV'r groups (P 〈0.01). A publication bias was not detected by funnel plots, the Egger method, or the Begg method. Conclusions Results of this meta-analysis showed that the treatments with IVB alone and combined IVB/IVT were similarly effective in improving the visual acuity, and, to some degree; combined IVB/IVT appeared to offer a marginal advantage over IVB in decreasing CMT in patients with DME. However, the addition of IV'I- resulted in intraocular pressure rise in some treated patients. 展开更多
关键词 intravitreal injection BEVACIZUMAB triamcinolone acetonide diabetic macular edema META-ANALYSIS
原文传递
玻璃体腔注射雷珠单抗联合曲安奈德治疗视网膜静脉阻塞继发黄斑水肿对黄斑区视网膜微循环的影响
10
作者 谢佩玲 张俐娜 +1 位作者 何佳玲 吕志刚 《中国药物与临床》 CAS 2024年第19期1247-1251,共5页
目的探究玻璃体腔注射雷珠单抗联合曲安奈德用于视网膜静脉阻塞(RVO)继发黄斑水肿(ME)对黄斑区视网膜微循环的影响。方法回顾性分析2022年1月至2023年9月在浙江大学医学院附属金华医院就诊的RVO-ME患者临床资料,观察组应用玻璃体腔注射... 目的探究玻璃体腔注射雷珠单抗联合曲安奈德用于视网膜静脉阻塞(RVO)继发黄斑水肿(ME)对黄斑区视网膜微循环的影响。方法回顾性分析2022年1月至2023年9月在浙江大学医学院附属金华医院就诊的RVO-ME患者临床资料,观察组应用玻璃体腔注射雷珠单抗联合曲安奈德治疗方案(197例,患眼229眼);对照组应用玻璃体腔注射雷珠单抗治疗方案(183例,患眼211眼),比较治疗前、治疗3个月后2组患者的视力相关参数、黄斑区视网膜微循环血流灌注参数、眼部血流动力学参数以及治疗期间的不良反应发生情况。结果治疗3个月后,2组患者的最佳矫正视力(BCVA)、中心视网膜厚度(CMT)、黄斑中心凹无血管区(FAZ)面积、FAZ周长较治疗前好转,且观察组[BCVA(0.43±0.09)、CMT(280±22)μm、FAZ面积(0.21±0.06)mm^(2)、FAZ周长(2.11±0.26)mm]低于对照组[BCVA(0.51±0.11)、CMT(301±30)μm、FAZ面积(0.27±0.07)mm^(2)、FAZ周长(2.29±0.20)mm](t=8.375、8.447、9.675、8.090,P均<0.05);2组患者浅表毛细血管丛(SCP)血流密度、深层毛细血管丛(DCP)血流密度、视网膜静脉收缩期峰值流速(PSV)、舒张末期流速(EDV)较治疗前提高,且观察组[SCP血流密度(46±3)%、DCP血流密度(47.3±3.8)%、PSV(24.4±1.4)cm/s、EDV(8.3±1.4)cm/s]高于对照组[SCP血流密度(44±3)%、DCP血流密度(46.0±3.5)%、PSV(23.4±1.3)cm/s、EDV(7.9±1.3)cm/s](t=5.120、3.753、6.673、3.122,均P<0.05)。2组患者的眼压、阻力指数(RI)和臂视网膜时间(ART)治疗前后差异无统计学意义(t=0.997、0.001、0.821,P>0.05)。治疗期间,观察组的不良反应发生率(6.6%)高于对照组(2.1%)(χ^(2)=4.324,P<0.05)。结论玻璃体腔注射雷珠单抗联合曲安奈德能够有效治疗RVO-ME患者,促进患者视力恢复,改善黄斑区视网膜微循环和眼部血流动力学,具有较好的安全性。 展开更多
关键词 玻璃体内注射 雷珠单抗 曲安奈德 视网膜静脉闭塞 黄斑水肿 黄斑区视网膜微循环
下载PDF
黄斑格栅样激光光凝联合玻璃体注射雷珠单抗、曲安奈德治疗视网膜静脉阻塞性黄斑水肿的效果及对视网膜血流参数的影响
11
作者 武雅贞 《临床医学研究与实践》 2024年第27期94-97,共4页
目的探究黄斑格栅样激光光凝联合玻璃体注射雷珠单抗、曲安奈德治疗视网膜静脉阻塞性黄斑水肿的效果。方法选择2019年1月至2022年10月我院收治的300例视网膜静脉阻塞性黄斑水肿患者为研究对象,以随机数字表法将其分为对照组和观察组,各... 目的探究黄斑格栅样激光光凝联合玻璃体注射雷珠单抗、曲安奈德治疗视网膜静脉阻塞性黄斑水肿的效果。方法选择2019年1月至2022年10月我院收治的300例视网膜静脉阻塞性黄斑水肿患者为研究对象,以随机数字表法将其分为对照组和观察组,各150例。对照组接受黄斑格栅样激光光凝+曲安奈德治疗,观察组在对照组基础上加施玻璃体注射雷珠单抗治疗。比较两组的治疗效果。结果观察组的治疗总有效率高于对照组(P<0.05)。治疗3个月后,观察组的视网膜中央收缩期峰值流速(PSV)、舒张期峰值流速(EDV)高于对照组(P<0.05)。出院时,观察组的结缔组织生长因子(CTGF)、血小板源性生长因子-C(PDGF-C)及血管内皮生长因子(VEGF)水平低于对照组(P<0.05)。治疗3个月后,观察组的三叶草像差、总高阶像差、球差及彗差优于对照组(P<0.05)。结论黄斑格栅样激光光凝联合玻璃体注射雷珠单抗、曲安奈德治疗视网膜静脉阻塞性黄斑水肿效果满意,可调节生长因子表达,改善视网膜血流参数及视觉质量,值得推广。 展开更多
关键词 黄斑格栅样激光光凝 玻璃体注射 雷珠单抗 曲安奈德 视网膜静脉阻塞性黄斑水肿 视网膜血流参数
下载PDF
玻璃体腔雷珠单抗、曲安奈德注射治疗对湿性老年黄斑变性患者内皮抑素及房水SDF1-α、LIF水平的影响 被引量:4
12
作者 张云 王倩 +5 位作者 陶锐 徐惠娣 陆庆 陈孝霞 刘修铎 赵婕 《分子诊断与治疗杂志》 2023年第1期85-89,共5页
目的 探讨玻璃体腔雷珠单抗、曲安奈德注射治疗对湿性老年黄斑变性(AMD)患者内皮抑素(ES)及房水基质细胞衍生因子1-α(SDF1-α)、人白血病抑制因子(LIF)水平的影响。方法 选取2016年1月至2021年12月上海市杨浦区市东医院收治的湿性AMD患... 目的 探讨玻璃体腔雷珠单抗、曲安奈德注射治疗对湿性老年黄斑变性(AMD)患者内皮抑素(ES)及房水基质细胞衍生因子1-α(SDF1-α)、人白血病抑制因子(LIF)水平的影响。方法 选取2016年1月至2021年12月上海市杨浦区市东医院收治的湿性AMD患者133例作为研究对象,根据治疗方式不同将患者分为对照组64例和观察组69例,对照组给予玻璃体腔注射曲安奈德治疗,观察组给予玻璃体腔注射雷珠单抗治疗。对比两组临床疗效、视力及眼压改善情况(BCVA、CFT、眼压)、炎性因子(ES、SDF1-α、LIF)、视功能损害眼病患者生存质量量表(SQOL-DVI)及不良反应发生情况。结果 观察组(94.20%)总有效率高于对照组(81.25%),差异有统计学意义(P<0.05)。观察组治疗后BCVA高于对照组,CFT、眼压均低于对照组,差异均有统计学意义(P<0.05)。治疗后,两组ES、SDF1-α和LIF水平均有所下降,且观察组治疗后ES、SDF1-α和LIF水平均明显低于对照组,差异均有统计学意义(P<0.05)。治疗后,两组SQOL-DVI各项评分均升高,且观察组治疗后明显高于对照组,差异均有统计学意义(P<0.05)。两组不良反应总发生率比较差异无统计学意义(P>0.05)。结论 玻璃体腔雷珠单抗与曲安奈德注射治疗湿性AMD疗效相比较,前者可更有效改善眼压及视力情况,调节ES、SDF1-α和LIF水平,更值得临床进一步推广应用。 展开更多
关键词 湿性老年黄斑变性 玻璃体腔雷珠单抗 曲安奈德 SDF1-α LIF
下载PDF
曲安奈德玻璃体腔注射治疗黄斑水肿的疗效及并发症分析
13
作者 郝晓璐 侯豹可 +2 位作者 郭晓会 邓丽琴 姚毅 《解放军医学院学报》 CAS 北大核心 2023年第11期1230-1234,1240,共6页
背景 曲安奈德可有效治疗各种类型的黄斑水肿,由于手术操作和制备工艺原因,可能引起各种并发症。目的 分析玻璃体腔内注射曲安奈德治疗黄斑水肿的疗效及相关并发症产生的原因。方法 选取2017年1月-2020年6月因黄斑水肿在我中心行玻璃体... 背景 曲安奈德可有效治疗各种类型的黄斑水肿,由于手术操作和制备工艺原因,可能引起各种并发症。目的 分析玻璃体腔内注射曲安奈德治疗黄斑水肿的疗效及相关并发症产生的原因。方法 选取2017年1月-2020年6月因黄斑水肿在我中心行玻璃体腔曲安奈德注药的患者。玻璃体腔内注射曲安奈德4 mg/0.1 mL,术后1 d、1个月、3个月、6个月评估视力及并发症情况。结果 189例患者(男104例、女85例) 189眼纳入分析,患者年龄45~82岁,平均年龄(53.3±9.6)岁。黄斑水肿病因:视网膜静脉阻塞97例(51.3%),糖尿病视网膜病变62例(32.8%),视盘血管炎(Ⅱ型) 20例(10.6%),白内障术后10例(5.3%)。术后随访6个月,患者黄斑水肿消退,注药术后最佳矫正视力均有不同程度提高[Md(IQR):0.2(0.1~0.4) vs 0.5(0.25~0.6),P<0.01]。相关性分析结果显示,术后视力与术前视力有较高的相关性(r=0.655,P<0.01)。进一步分析四组不同病因导致的黄斑水肿患者对注药术的反应情况,统计结果显示注药术后各组视力均提高,四组差值比较差异无统计学意义(P>0.05)。术后主要并发症:高眼压42例(22.2%),白内障46例(24.3%),结膜下出血21例(6.3%),角膜上皮剥脱7例(2.1%),非感染性眼内炎5例(1.5%),感染性眼内炎1例(0.3%)。结论 玻璃体腔内注射曲安奈德可有效治疗黄斑水肿,改善视功能;但仍存在发生严重并发症的可能,需要严格进行围术期感染相关危险因素控制并进行赋形剂改良以降低严重并发症的发生率。 展开更多
关键词 曲安奈德 玻璃体腔注药 黄斑水肿 并发症 视力
下载PDF
内界膜剥除联合曲安奈德对糖尿病性黄斑水肿患者视力水平及效果分析 被引量:2
14
作者 李云飞 任骞 +4 位作者 孙朝晖 李丽 孙瑞雪 苏宪 于华 《中华保健医学杂志》 2023年第3期324-326,共3页
目的 探讨内界膜剥除联合曲安奈德对糖尿病性黄斑水肿患者视力水平及效果。方法 前瞻性选取2018年1月~2022年1月在石家庄市人民医院眼科接受治疗的糖尿病性黄斑水肿病例102例,随机数表法分为观察组和对照组,各51例。两组均施展内界膜剥... 目的 探讨内界膜剥除联合曲安奈德对糖尿病性黄斑水肿患者视力水平及效果。方法 前瞻性选取2018年1月~2022年1月在石家庄市人民医院眼科接受治疗的糖尿病性黄斑水肿病例102例,随机数表法分为观察组和对照组,各51例。两组均施展内界膜剥除术,在术后,对照组未作特殊处理,观察组采用曲安奈德玻璃体腔内注射。对比两组总有效率、视网膜厚度、最佳矫正视力、眼压、各项评分(舒适度、睡眠及生活质量)。结果 观察组治疗总有效率更高于对照组,差异有统计学意义(P <0.05)。治疗后,对比于对照组,观察组中黄斑中心凹视网膜厚度与中央视网膜厚度均更低,最佳矫正视力更高,眼压更高,差异有统计学意义(P <0.05)。治疗后,与对照组相比,观察组中舒适度评分、生活质量评分均更高,观察组中睡眠质量评分更低,差异有统计学意义(P <0.05)。结论 对于糖尿病性黄斑水肿患者,在内界膜剥除术后应用曲安奈德玻璃体腔内注射,可更好地控制黄斑水肿情况,促使黄斑中心凹和中央视网膜厚度减少,有利于改善视力,对患者睡眠质量的改善作用良好。 展开更多
关键词 糖尿病性黄斑水肿 内界膜剥除术 曲安奈德 玻璃体腔内注射
下载PDF
玻璃体腔注射曲安奈德治疗白内障术后人工晶状体眼黄斑囊样水肿的效果
15
作者 白小龙 穆挺 +1 位作者 李晶明 陶李 《临床医学研究与实践》 2023年第32期25-28,共4页
目的探讨玻璃体腔注射曲安奈德治疗白内障术后人工晶状体眼黄斑囊样水肿(PCME)的效果。方法选取2018年8月至2021年12月收治的15例(15眼)白内障术后PCME患者作为研究对象,给予玻璃体腔注射曲安奈德治疗。比较患者注药前、注药后不同时间... 目的探讨玻璃体腔注射曲安奈德治疗白内障术后人工晶状体眼黄斑囊样水肿(PCME)的效果。方法选取2018年8月至2021年12月收治的15例(15眼)白内障术后PCME患者作为研究对象,给予玻璃体腔注射曲安奈德治疗。比较患者注药前、注药后不同时间点的最佳矫正视力(BCVA)、眼压、黄斑中心凹厚度(CMT)和并发症发生情况。结果患者注药前、注药后1 d及1、3、6个月的BCVA比较,差异具有统计学意义(P<0.05);注药后1 d及1、3、6个月,患者的BCVA优于注药前(P<0.05);注药后1、3、6个月,患者的BCVA优于注药后1 d(P<0.05)。注药前、注药后1 d及1、3、6个月的眼压比较,差异无统计学意义(P>0.05)。注药前及注药后1、3、6个月的CMT比较,差异具有统计学意义(P<0.05);注药后1、3、6个月,患者的CMT小于注药前(P<0.05)。注药后1 d及1、3、6个月,所有患者未出现眼部和全身并发症。结论玻璃体腔注射曲安奈德能安全、有效地降低白内障术后PCME患者的黄斑水肿程度,改善视力。 展开更多
关键词 人工晶状体眼黄斑囊样水肿 曲安奈德 玻璃体腔注射
下载PDF
康柏西普玻璃体腔注射对糖尿病视网膜病变患者视力的影响 被引量:91
16
作者 韩姬 王玲 +2 位作者 刘伟仙 孙宏亮 蔡维 《中国全科医学》 CAS CSCD 北大核心 2015年第5期502-506,共5页
目的探讨康柏西普玻璃体腔注射治疗糖尿病视网膜病变对于视力的影响。方法选取2014年2—6月在海南医学院附属医院进行诊治的糖尿病视网膜病变患者72例(72眼),根据随机数字表法将其分为治疗组和对照组,各36例。患者均给予玻璃体腔一次性... 目的探讨康柏西普玻璃体腔注射治疗糖尿病视网膜病变对于视力的影响。方法选取2014年2—6月在海南医学院附属医院进行诊治的糖尿病视网膜病变患者72例(72眼),根据随机数字表法将其分为治疗组和对照组,各36例。患者均给予玻璃体腔一次性注射药物治疗,对照组注射曲安奈德0.1 ml,治疗组注射康柏西普0.1 ml。在治疗前及治疗后1、3个月采用标准视力表对患者进行最佳矫正视力(BCVA)检查;在治疗前及治疗后1个月进行光相干断层扫描(OCT)检测视网膜厚度;在治疗前及治疗后1个月进行多焦视网膜电流图(mf ERG)检查分析N1波(第1个负波)潜伏期的变化期间;记录治疗后1个月内出现的并发症,包括前房炎性反应、角膜水肿、高眼压等;在治疗后3个月采用中文版低视力者生活质量量表(CLVOOL)对患者进行生活质量的调查。结果两组不同时间BCVA比较,差异有统计学意义(P<0.05);组间比较显示:治疗组治疗后3个月BCVA高于对照组(P<0.05);组内比较显示:两组在治疗后1、3个月BCVA均高于治疗前(P<0.05)。治疗前,两组视网膜厚度、N1波潜伏期比较,差异无统计学意义(P>0.05);治疗组治疗后1个月视网膜厚度低于对照组,N1波潜伏期短于对照组(P<0.05);治疗组与对照组在治疗后1个月视网膜厚度低于治疗前,N1波潜伏期短于治疗前(P<0.05)。在治疗后1个月,治疗组前房炎性反应、角膜水肿、高眼压并发症发生率均低于对照组(P<0.05)。治疗后3个月,治疗组自理能力、活动能力、社交与心理评分均高于对照组(P<0.05)。结论康柏西普玻璃体腔注射治疗糖尿病视网膜病变能有效改善视网膜功能,安全性更好,从而有利于视力的快速恢复,提高生活质量。 展开更多
关键词 康柏西普 玻璃体内注射 糖尿病视网膜病变 视力 曲安奈德
下载PDF
玻璃体内注射雷珠单抗与曲安奈德治疗糖尿病黄斑水肿的疗效对比分析 被引量:43
17
作者 王博 吴京 +2 位作者 马明 李萍萍 于健 《眼科新进展》 CAS 北大核心 2015年第3期246-249,共4页
目的对比分析玻璃体内注射雷珠单抗与曲安奈德治疗糖尿病黄斑水肿的临床疗效。方法选取就诊于我院眼科的糖尿病黄斑水肿患者47例(48眼),病程6~14个月;分为雷珠单抗组24例24眼,曲安奈德组23例24眼;分别给予玻璃体内注射雷珠单抗0.05 m... 目的对比分析玻璃体内注射雷珠单抗与曲安奈德治疗糖尿病黄斑水肿的临床疗效。方法选取就诊于我院眼科的糖尿病黄斑水肿患者47例(48眼),病程6~14个月;分为雷珠单抗组24例24眼,曲安奈德组23例24眼;分别给予玻璃体内注射雷珠单抗0.05 mL与曲安奈德0.05 mg,比较两组治疗1周、1个月、3个月、6个月患眼的最佳矫正视力、黄斑中心凹视网膜厚度、眼压及眼底黄斑区荧光素渗漏情况,观察治疗后的效果。结果雷珠单抗组与曲安奈德组治疗后1周、1个月、3个月患眼的最佳矫正视力均得到提高,分别为0.08±0.02与0.06±0.03、0.21±0.03与0.17±0.05、0.29±0.07与0.27±0.04,治疗后短期内两组间差异无统计学意义(P值分别为0.082、0.092、0.320);治疗6个月后,曲安奈德组患眼的最佳矫正视力(0.18±0.03)有5例出现回降现象;而雷珠单抗组患眼的最佳矫正视力(0.28±0.09)变化趋于稳定,两组间的差异有统计学意义(P=0.003)。治疗后1周、1个月、3个月、6个月雷珠单抗组与曲安奈德组患眼的黄斑中心凹视网膜厚度分别为(336.00±94.71)μm与(378.00±89.74)μm、(251.00±63.55)μm与(273.00±81.29)μm、(263.00±59.42)μm与(267.00±49.32)μm、(238.00±42.61)μm与(298.00±33.27)μm,治疗后各时间点两组间的差异均无统计学意义(P=0.127、0.071、0.053、0.058)。另外,治疗后各时间点两组的眼压均在正常范围内,并且黄斑区荧光渗漏均无明显增强现象。结论玻璃体内注射雷珠单抗和曲安奈德治疗糖尿病黄斑水肿,均能有效控制糖尿病视网膜病变患者病情发展并能改善视力。两种疗法的疗效在短期内差异无统计学意义,治疗6个月后,雷珠单抗疗效的稳定性优于曲安奈德。 展开更多
关键词 糖尿病黄斑水肿 雷珠单抗 曲安奈德 玻璃体内注射
下载PDF
贝伐单抗与曲安耐德玻璃体腔注射治疗糖尿病黄斑水肿近期疗效的比较 被引量:11
18
作者 王丽丽 张雯 +2 位作者 李立婕 金丽英 霍敏 《中华实验眼科杂志》 CAS CSCD 北大核心 2011年第6期559-563,共5页
背景黄斑水肿是糖尿病最常见的损害视力的原因,玻璃体腔注射贝伐单抗和曲安奈德(TA)的方法已被用于糖尿病黄斑水肿(DME)的治疗,但2种药物的临床效果和安全性的评价和比较是非常必要的。目的评价和比较玻璃体腔注射贝伐单抗和TA治... 背景黄斑水肿是糖尿病最常见的损害视力的原因,玻璃体腔注射贝伐单抗和曲安奈德(TA)的方法已被用于糖尿病黄斑水肿(DME)的治疗,但2种药物的临床效果和安全性的评价和比较是非常必要的。目的评价和比较玻璃体腔注射贝伐单抗和TA治疗DME的疗效及安全性。方法收集经OCT及荧光素眼底血管造影(FFA)确诊为DME者98例98眼,按就诊的先后时间分为贝伐单抗组和TA组,每组各49例49眼。贝伐单抗组患眼于角膜缘后4mm处行玻璃体腔注射贝伐单抗0.05ml(1.25mg),TA组玻璃体腔注射TA0.1ml(4mg)。术后4、8、12周观察并比较2组患眼的视力(国际视力表视力)、黄斑中心视网膜厚度(CMT)、眼压及并发症的情况。结果所有患者均完成临床试验。2组患者的人口基线特征比较差异均无统计学意义(P〉0.05)。TA组和贝伐单抗组患眼玻璃体注射后各时间点视力与注射前比较均明显提高,差异均有统计学意义(P〈0.01),贝伐单抗组在治疗后4~8周时视力最好,注射12周时视力较8周下降,差异有统计学意义(t=-11.579,P〈0.05);玻璃体注射前后不同时间2组患眼间的视力比较差异均无统计学意义(P〉0.05)。玻璃体注射前后不同时问2组患眼间的CMT值比较差异均无统计学意义(P〉O.05),但TA组和贝伐单抗组患眼玻璃体注射后各时间点CMT值与注射前比较均明显减少,差异均有统计学意义(P〈O.01)。TA组患眼玻璃体注射后4、8、12周眼压值均明显高于贝伐单抗组,差异均有统计学意义(P〈0.05、P〈0.01),TA组患眼玻璃体注射后4、8、12周眼压值均高于注射前基线值(P〈0.01),贝伐单抗组4、8、12周眼压值与注射前比较差异无统计学意义(P〉0.05)。TA组患眼玻璃体注射后眼压升高的发生率14.3%。结论玻璃体腔注射贝伐单抗治疗DME与TA玻璃体注射相比均能提高视力,减轻黄斑水肿。TA显效时间较贝伐单抗快,但贝伐单抗安全性较好。 展开更多
关键词 贝伐单抗 曲安奈德 糖尿病 黄斑水肿 玻璃体注射 眼压
下载PDF
曲安奈德玻璃体腔注射联合黄斑格栅样光凝治疗黄斑水肿的临床研究 被引量:13
19
作者 乔宝笛 戴涛 +1 位作者 帖彪 陈鹏 《中华实验眼科杂志》 CAS CSCD 北大核心 2012年第8期734-738,共5页
背景糖皮质激素玻璃体腔注射治疗黄斑水肿的l临床效果已得到证实,其代表性药物为曲安奈德。但曲安奈德局部应用联合黄斑格栅样光凝治疗黄斑水肿的疗效及安全性值得关注。目的评价曲安奈德玻璃体腔注射联合黄斑格栅样光凝治疗黄斑水肿... 背景糖皮质激素玻璃体腔注射治疗黄斑水肿的l临床效果已得到证实,其代表性药物为曲安奈德。但曲安奈德局部应用联合黄斑格栅样光凝治疗黄斑水肿的疗效及安全性值得关注。目的评价曲安奈德玻璃体腔注射联合黄斑格栅样光凝治疗黄斑水肿的疗效及安全性。方法采取队列研究试验设计,按照纳入标准收集糖尿病性黄斑水肿或视网膜静脉阻塞性黄斑水肿患者120例120眼,按随机数字表法将患者随机分为试验组和对照组,两组人口基线特征匹配。试验组实施玻璃体腔注射曲安奈德联合黄斑格栅样光凝,对照组仅行黄斑格栅样光凝,分别于术后1周,1、3、6个月行最佳矫正视力、眼压、光学相干断层扫描(OCT)、荧光素眼底血管造影(FFA)检查,对检查指标进行组间比较,对试验组术后检测结果与术前值进行比较。结果与玻璃体腔注射前视力比较,试验组在注射后1周、1、3、6个月视力均有明显提高,差异均有统计学意义(均P=0.000),而对照组治疗后各时间点的视力与治疗前比较差异均无统计学意义(P〉0.05);治疗后各时间点对照组的视力均明显低于试验组,差异均有统计学意义(P=0.037、0.000、0.002、0.046)。玻璃体腔注射后各时间点试验组黄斑水肿明显减轻,黄斑中心凹视网膜神经上皮层厚度明显下降,差异均有统计学意义(均P=0.000),而对照组黄斑中心凹视网膜神经上皮层厚度与治疗前比较差异均无统计学意义(P〉0.05),玻璃体腔注射后各时间点试验组黄斑中心凹视网膜神经上皮层厚度均显著低于对照组,差异均有统计学意义(P〈0.05)。试验组中7例在玻璃体腔注射后4~6个月黄斑水肿复发,占11.67%;玻璃体腔注射后11例眼压升高至21mmHg以上,占14.1%。结论曲安奈德玻璃体腔注射联合黄斑格栅样光凝可有效治疗黄斑水肿,但少数患者在6个月内出现复发及眼压升高。 展开更多
关键词 曲安奈德 玻璃体腔注射 格栅样光凝 黄斑水肿
下载PDF
玻璃体腔内注射曲安奈德治疗渗出型老年性黄斑变性临床观察 被引量:12
20
作者 彭娟 沙翔垠 +3 位作者 杨瑞明 郑瑜 吴兴萍 郭露萍 《实用医学杂志》 CAS 北大核心 2012年第14期2426-2428,共3页
目的:观察玻璃体腔内注射曲安奈德治疗渗出型老年性黄斑变性的疗效和安全性。方法:收集2011年1月至2012年1月渗出型老年性黄斑变性患者11例11眼为治疗组,收集同期7例患者为对照组。治疗组患者均接受玻璃体腔内注射曲安奈德4mg。对照组... 目的:观察玻璃体腔内注射曲安奈德治疗渗出型老年性黄斑变性的疗效和安全性。方法:收集2011年1月至2012年1月渗出型老年性黄斑变性患者11例11眼为治疗组,收集同期7例患者为对照组。治疗组患者均接受玻璃体腔内注射曲安奈德4mg。对照组采用保守治疗。观察术前术后视力及眼压情况,荧光造影及光学相干视网膜断层成像检测黄斑情况。结果:治疗组术后患者视力均有提高,术后3个月视力提高明显平均值0.32±0.12。术后视力提高值与术前视力呈负相关。术后眼压值升高,术后1个月眼压值为(20.15±9.45)mmHg,术后3个月眼压值降至正常范围,平均眼压值(18.57±8.76)mmHg。术后3个月黄斑中心凹厚度变薄为(219.12±12.81)μm。与对照组比较,治疗组术后3个月视力有明显提高,黄斑中心凹厚度明显变薄。结论:玻璃体腔内注射曲安奈德能有效提高渗出型老年性黄斑变性患者的视力,有一过性眼压升高是安全,有效的治疗方法之一。 展开更多
关键词 黄斑变性 玻璃体腔注射 曲安奈德
下载PDF
上一页 1 2 7 下一页 到第
使用帮助 返回顶部